
Radiation oncologist @UniPadova | #pcsm #hncsm #radonc
Joined May 2019
- Tweets110
- Following303
- Followers178
- Likes656
Badr El Khouzai retweeted
Across 3 prospective studies, the signal for post-prostatectomy SBRT in 5 fx is increasingly consistent: feasible, low toxicity & excellent in-field control. StereoBed randomized data show no PRO/toxicity penalty; POPART/esSBRT show few local failures.
#ASTRO26 @rtdess @HimanshuNagarMD @RadOncDocJ @NRGonc @ASTRO_org @urotoday @ChadTangMD @TylerSbrt @SbrtSean @jryckman3 @seanmmcbride
Badr El Khouzai retweeted
Woke up to see the @QuadShotNews mentioning new @myESMO guidelines for prostate cancer.
Congrats to @PBlanchardMD @stefanofanti4 @Silke_Gillessen @Prof_Nick_James @piet_ost @PCaParker @Tilki_De @alison_tree @ZilliThomas et al on this Oscar of Oncology award from USA 🇺🇸 😀👏
Badr El Khouzai retweeted
Extremely excited to share our latest article published @TheLancetOncol a few hours ago: authors.elsevier.com/a/1mYT6….
The WOLVERINE individual patient meta-analysis was an international collaboration and part of X-MET collaboration. Goal was to evaluate MDT in oligomet prostate ca.
Badr El Khouzai retweeted
🚨 New @TheLancet Seminar: #ProstateCancer🚨
Key takeaways ⬇️
🧬 Biology & heterogeneity matter
Prostate cancer isn’t one disease—molecular subtypes (eg, BRCA2, PTEN, AR alterations) increasingly guide therapy
🔍 Diagnosis has evolved
MRI-first pathways + PSMA PET outperform conventional imaging, but raise questions about stage migration
⏸️ Active surveillance is standard
Preferred for low-risk disease and select intermediate-risk pts—reduces overtreatment with excellent long-term outcomes
🏥 Local therapy ≈ equivalent cancer control
Surgery, EBRT, brachytherapy all effective—decision hinges on toxicity profiles & patient preferences
🔥 High-risk disease = multimodal
RT + long-term ADT ± ARPIs now core; surgery often part of a combined strategy
🌍 Metastatic landscape transformed
ADT + ARPI (± docetaxel) improves OS; triplet therapy for fit, high-volume pts
🎯 Targeted & radioligand therapies
PARP inhibitors (BRCA-driven benefit) and Lu-177–PSMA are reshaping mCRPC care
🤝 Shared decision-making is central
Toxicity, quality of life, and sequencing remain key unanswered questions
Essential read for anyone treating prostate cancer 👇
@PCF_Science @PCFnews @urotoday @UrologyTimes
@Ecastromarcos @alison_tree
🔗shorturl.at/xZti6
Badr El Khouzai retweeted
Replying to @h_mehanna
@h_mehanna @H_N_C_I_G presents results of CompARE trial at #ESMO26 on the use of induction and adjuvant durvalumab to concurrent CRT for oropharyngeal cancer.
No benefit overall in DFS or OS.
possible benefit in high risk patients.
No added toxicity.
Badr El Khouzai retweeted
STOPCAP at #ESMO26
Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS.
Restricted to <5 bone or low volume mets on conventional imaging.
No interaction with other patient/tumor characteristics.
Badr El Khouzai retweeted
🧬 Cribriform architecture changes the story in localized prostate cancer.
🔥 ProtecT 15-year biopsy re-review shows who really needs treatment vs surveillance.
🎯 n = 712 with available slides (13 % cribriform+)
💊 Arms:
▫️ Active monitoring
▫️ Radical prostatectomy
▫️ Radiotherapy + neoadjuvant ADT
📊 Key Results
• Cribriform + → ↑ metastasis risk (HR 3.61, 95 % CI 1.60-8.11)
• RT + ADT → lowest metastasis (HR 0.35 vs active monitoring)
• Surgery → HR 0.52 vs active monitoring (NS)
• 15-yr metastasis (cribriform +): AM 25 % | Surg 26 % | RT + ADT 8 %
• Cribriform –: 7 % | 4 % | 3 %
✅ Takeaway:
Cribriform + = treat aggressively (RT + ADT best long-term control)
Cribriform – = active surveillance still safe for most patients.
📖 Sushentsev et al. JAMA Oncology 2025. 🔗 doi.org/10.1001/jamaoncol.20…
#OncoTwitter #MedTwitter #ProstateCancer #UroOnc
@OncoAlert @myesmo @esmo_open @ASCO @JAMAOnc
Badr El Khouzai retweeted
De escalated therapy is safe for stage IIA-IIB seminoma!
✅No recurrence since initial presentation in 2021.
✅No severe toxicity.
✅Secondary malignancies only outside of radiotherapy fields.
Long term outcomes of SAKK 01/10 by @Alex_Papachris at #ESMO2
Badr El Khouzai retweeted
The RAMPP trial has landed ‼️
Congratulations to the authors for this great work!!
It compared best systemic therapy + RP (with extended LND) to BST alone for patients with de-novo synchronous oligometastatic PCa, defined as =< 5 bone mets. BST consisted of lifelong ADT. It closed early due to STAMPEDE results. Cancer-Specific mortality was the primary enpoint. Clinical progression and OS were secondary endpoints.
An X-torial
1/n
@euplatinum @urotoday @dr_coops @chapinmd @pcaparker @soum_roy_radonc @drspratticus @drandrewloblaw @tylersbrt @seanmmcbride @sbrtsean @alison_tree @vedangmurthy @piet_ost @paulsargos @jryckman3 @5_utr @protonstorey @docpriyamvada @_shankarsiva @alexsherrymd @albertobossial @xristodouleas @amarukishan @zklaassen_md @themednet
#OncoTwitter #ProstateCancer #RadOnc #UroOnc @oncoalert
sciencedirect.com/science/ar…
Badr El Khouzai retweeted
STORM-PEACE V trial reported by @ZilliThomas #ESTRO25
Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each)
Improves
Biochemical PFS
Locoregional PFS
MFS
ADT free survival
Tox NS
ENI clear SOC
Online @TheLancetOncol
Cc @piet_ost
Badr El Khouzai retweeted
SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03.
Convenient
Fast
Similar outcomes than post op brachy
Mostly VMAT homogeneous plans
#ESTRO25
Badr El Khouzai retweeted
Bladder preservation is a philosophy—not just a protocol.
A 15-year journey in bladder preservation at @RadOncTMC . @TataMemorial @ACTREC_TMC
From pioneering Adaptive Radiotherapy (ART) to safely transitioning to hypofractionation, our story, in @IJROBP #RadOnc #bladdercancer
Badr El Khouzai retweeted
Kinetics of PSMA PET signal after radiotherapy in 217 prostate cancer lesions: It takes multiple months for the uptake to decrease (> 6 months). Beware of "pseudo-progression" on PSMA PET performed shortly after RT. @RO_GreenJournal @masatoshihotta @UCLA
sciencedirect.com/science/ar…
Badr El Khouzai retweeted
Thanks to @DavidSherMD for the invitation to contribute to this special issue in Seminars in Radiation Oncology on #precisionradiotherapy
Personalising #NasopharyngealCancer #NPC : Systemic Therapy and Radiotherapy
sciencedirect.com/science/ar…
Badr El Khouzai retweeted
Timing matters? ⏰ Morning ☢️⬆️ survival in NPC without added toxicity. Should we rethink RT scheduling? 🤔@OncoAlert
🎯Objective:
•Investigate the impact of ☢️ timing (morning, afternoon, night) on OS and toxicity in NPC
🔬Methods:
•Retrospective analysis of 1,040 NPC 👥 treated w/ IMRT
•👥 grouped by treatment ⌚: Morning (6:00-11:59), Afternoon (12:00-17:59), Night (18:00-24:00)
•PSM and Cox used to ⚖️ confounders
📊Results:
•Morning RT ⬆️ OS
•HR: Afternoon (5.88, P=.004), Night (4.81, P=.018)😱
•N🚫 difference in acute toxicity between groups
🗣Conclusion:
Morning ☢️ ⬆️survival for NPC. Prospective studies are needed to confirm findings❗️
Badr El Khouzai retweeted
PEACE-1 RT is now published online at @TheLancet
Some differences with STAMPEDE
Key messages: RT to prostate in M1 #prostatecancer
1. improves rPFS but not OS in low volume
2. improves CRPC-FS & reduces serious GU SAE irrespective of volume
Full text: thelancet.com/journals/lance…
Badr El Khouzai retweeted
Excited to see HN004 out in publication!
In Star Wars terms, if HN005 is Seventy Gray Strikes Back, then HN004 is The Rise of Cetuximab
thelancet.com/journals/lanon…
Badr El Khouzai retweeted
Delighted to share the results of #PACE B trial, published in @NEJM today
5 fraction SBRT is non inferior to CRT!
nejm.org/media/doi/full/10.1…
@alison_tree @ICR_CTSU @EmmaHall71 @royalmarsdenNHS @DrAndrewLoblaw @cpeedell @DrTolan @ProfJOSullivan @DrSuneil_PCa


























































